Samantha Lorusso1, David Kline2, Amy Bartlett1, Miriam Freimer1, Julie Agriesti1, Ahmed A Hawash3, Mark M Rich3, John T Kissel1, W David Arnold1. 1. Division of Neuromuscular Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, Columbus, Ohio, 43210, USA. 2. Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, USA. 3. Department of Neuroscience, Cell Biology and Physiology, Wright State University, Dayton, Ohio, USA.
Abstract
INTRODUCTION: Paramyotonia congenita (PMC) is a nondystrophic myotonic disorder that is believed to be caused by a defect in Nav 1.4 sodium channel inactivation. Ranolazine, which acts by enhancing slow inactivation of sodium channels, has been proposed as a therapeutic option, but in vivo studies are lacking. METHODS: We conducted an open-label, single-center trial of ranolazine to evaluate efficacy and tolerability in patients with PMC. Subjective symptoms of stiffness, weakness, and pain as well as clinical and electrical myotonia were evaluated. Baseline measures were compared with those after 4 weeks of treatment with ranolazine. RESULTS: Ranolazine was tolerated well without any serious adverse events. Both subjective symptoms and clinical myotonia were significantly improved. Duration of myotonia was reduced according to electromyography, but this change was not statistically significant in all tested muscles. DISCUSSION: Our findings support the use of ranolazine as a treatment for myotonia in PMC and suggest that a randomized, placebo-controlled trial is warranted. Muscle Nerve 59:240-243, 2019.
INTRODUCTION:Paramyotonia congenita (PMC) is a nondystrophic myotonic disorder that is believed to be caused by a defect in Nav 1.4sodium channel inactivation. Ranolazine, which acts by enhancing slow inactivation of sodium channels, has been proposed as a therapeutic option, but in vivo studies are lacking. METHODS: We conducted an open-label, single-center trial of ranolazine to evaluate efficacy and tolerability in patients with PMC. Subjective symptoms of stiffness, weakness, and pain as well as clinical and electrical myotonia were evaluated. Baseline measures were compared with those after 4 weeks of treatment with ranolazine. RESULTS:Ranolazine was tolerated well without any serious adverse events. Both subjective symptoms and clinical myotonia were significantly improved. Duration of myotonia was reduced according to electromyography, but this change was not statistically significant in all tested muscles. DISCUSSION: Our findings support the use of ranolazine as a treatment for myotonia in PMC and suggest that a randomized, placebo-controlled trial is warranted. Muscle Nerve 59:240-243, 2019.
Authors: M C Koch; K Steinmeyer; C Lorenz; K Ricker; F Wolf; M Otto; B Zoll; F Lehmann-Horn; K H Grzeschik; T J Jentsch Journal: Science Date: 1992-08-07 Impact factor: 47.728
Authors: Nesrine El-Bizri; Kristopher M Kahlig; John C Shyrock; Alfred L George; Luiz Belardinelli; Sridharan Rajamani Journal: Channels (Austin) Date: 2011-03-01 Impact factor: 2.581
Authors: Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland Journal: Muscle Nerve Date: 2020-05-27 Impact factor: 3.217